Navigation Links
Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancer
Date:12/10/2010

SAN ANTONIO The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.

Results of this study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010, and demonstrate the value of CTCs in early breast cancer, independent of estrogen-receptor or HER2 status and before use of adjuvant therapy.

The benefit of using CTCs to predict risk for recurrence and death in metastatic breast cancer patients has been shown in a number of studies, and use of a CTC test in metastatic breast cancer has been approved by the Food and Drug Administration.

The CTCs found in this study are likely evidence that a tumor is shedding breast cancer cells, said lead researcher Brigitte Rack, M.D., head of the department of gynecological oncology at the Women's Hospital at the University of Munich, Germany. "The CTCs might have been released from the primary tumor before these patients underwent surgery, and the expression of stem cell markers on disseminated tumors cells has been shown by several groups."

Survival of these CTCs after chemotherapy further suggests they are cancer stem cells, Rack added.

Researchers with this study are testing the effectiveness of two different chemotherapy regimens and extended adjuvant bisphosphonate treatment in early breast cancer. SUCCESS' efficacy data are expected to be released next year.

Results of this study showed that 21.5 percent of patients had one or more CTC in their blood before the start of adjuvant treatment. These patients were more frequently node-positive, but no other linkage could be made with tumor size or grade or HER2 status.

Breast cancer recurred in 114 patients, and 66 patients died. Being CTC-positive was a significant independent predictor for both disease-free and overall survival. Patients with one to four CTCs had an 88 percent increased risk of early breast cancer recurrence and a 91 percent increased risk of death from breast cancer, according to Rack.

Prognosis was worse in patients with five or more CTCs; these patients had a fourfold risk of cancer recurrence and a threefold risk for death from the disease.

"Our study suggests testing CTCs may prove to be important to help individualize therapy for early-stage breast cancer where no measurable tumor is present," she said. "Patients who seem to be at high risk due to CTC may benefit from additional treatment options, and those that don't have CTCs may be spared side effects of some treatments."

She added, however, that prospectively randomized trials are necessary to show an improvement of survival based on CTC diagnostics. Trials testing this notion are either ongoing or about to start in Europe and the United States, according to Rack.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Poor breast cancer prognosis associated with presence of circulating tumor, cancer stem cells
2. Circulating tumor cells can provide real-time information on patients current disease state
3. Circulating tumor cells correlate with poorer survival in pancreatic cancer patients
4. Survival in metastatic breast cancer directly linked to circulating tumor cells
5. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
6. Revisiting the need to detect circulating tumor cells
7. A double block of blood vessels to starve cancerous tumors
8. Protein targeted to stop melanoma tumor growth
9. Tumors bring their own support cells when forming metastases
10. New prostate cancer imaging shows real-time tumor metabolism
11. Researchers shine light on how some melanoma tumors evade drug treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at ... his internship in internal medicine at the Emory University and dermatology training at ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... ... of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly ... management information has been condensed to a single page, maximizing usability and improving ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video can get a ... The winner will earn a $1,000 scholarship and have his or her video posted ... the deadline is May 31, with the winner announced on June 9. , The ...
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) ... who seek access to the Network’s programs and services in the greater Pittsburgh region. ... care appointments will be offered one for that same afternoon. , AHN ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: